In a meta-analysis 6 of eight trials with 60080 patients (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6, and AMPLITUDE-O) , treatment with a GLP-1 receptor agonist led to a 14% relative risk reduction in three-point MACE (HR 086 [95% CI 080093]
learn more at ro.co
Most people experience mild to moderate intensity headaches rather than severe migraines, though pre-existing migraine conditions can increase severity
Previous reviews of clinical trials evaluated the effect of the SGLT-2i and GLP-1RA combination on metabolic factors, and they showed a mostly positive effect [65, 66]
This peptide, studied for its structural modifications and extended half-life, has been hypothesized to possess unique properties that may contribute to its relevance across various investigative domains